GCC medical tourism market forecast to reach $890 million by 2032, growing at 10.26% CAGR

The GCC medical tourism market is forecast to reach USD 889.97 million by 2032, growing at a compound annual rate of 10.26%, according to a market sizing study published by Credence Research in October 2025. For UAE healthcare providers, the projection sets a revenue ceiling with a fixed timeline.

UAE's position in the GCC market

The UAE competes for medical tourists on two bases: specialist expertise unavailable in smaller GCC markets, and shorter wait times than Saudi Arabia's public system. Dubai and Abu Dhabi are the primary inbound destinations. The Dubai Health Authority (DHA) has operated a dedicated health tourism licensing framework since 2016, requiring facilities that market to international patients to hold a separate permit from their standard facility license. The Department of Health Abu Dhabi (DOH) runs the Shifa referral program, directing international patients to accredited facilities for high-acuity procedures.

Inbound medical tourism draws from two patient pools: nationals of Yemen, Libya, and Iraq who lack access to comparable treatment at home, and Saudi nationals seeking procedures outside the Kingdom's public queue. Oncology, cardiac surgery, and orthopedics account for the largest share of clinical revenue from both groups.

Accreditation as a commercial requirement

The Ministry of Health and Prevention (MOHAP) updated its health tourism licensing requirements in 2024, adding a dedicated permit category for facilities that actively recruit international patients. This creates a three-regulator compliance environment for providers operating across emirates and pursuing cross-border patients.

International accreditation is now a commercial baseline. Four factors define provider competitiveness in the GCC inbound market:

• JCI certification is a standard requirement among GCC referral agents and travel insurance companies coordinating medical travel
• Competing destinations including Thailand, India, and Jordan have grown JCI-accredited facility counts, raising the threshold UAE providers must clear on quality credentials
• MOHAP, DHA, and DOH each require separate health tourism permits, creating multi-jurisdiction compliance costs for cross-emirate operators
• Language services and dedicated case management are now baseline expectations for international patient programs, not add-ons priced separately

Investment timing

A market growing at 10.26% annually through 2032 gives UAE providers roughly seven years to build inbound capacity. JCI accreditation takes 18 to 24 months. Dedicated international patient infrastructure takes longer. Investment decisions made in 2025 and 2026 will determine which facilities capture a meaningful share of that USD 890 million market.

CEOs and CFOs modeling medical tourism as a revenue line should account for the full program cost: licensing fees to DHA, DOH, or MOHAP depending on emirate; accreditation costs; case management and translation staffing; and the margin differential between international self-pay patients and locally insured cases. The Credence Research projections cover gross market spend across the GCC, not net revenue to UAE providers, and the spread between those two figures is substantial.